ESMO 2023 GI Cancer Highlights – Codebreak300, CABINET, GASTFOX

    (12)

    In discussion with Dr. Rachna Shroff covering the ESMO 2023 GI Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Shroff

    Key Points:

    • Codebreak300 – Sotorasib plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer
    • CABINET – Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus
    • GASTFOX – Evaluate FOLFOX With or Without Docetaxel (TFOX) as First Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma